Watch These Hot Ones: Caterpillar Inc., Facebook Inc (NASDAQ:FB), Alphabet Inc (NASDAQ:GOOG), Symetra Financial Corporation (NYSE:SYA), BioLineRx, (NASDAQ:BLRX)

On 19 January, Caterpillar Inc. (NYSE:CAT) shares decreased -1.40% and was closed at $59.03. CAT EPS growth in last 5 year was 32.70%. Caterpillar Inc. (NYSE:CAT) year to date (YTD) performance is -12.05%.

Caterpillar Inc. (NYSE:CAT) voted to maintain the quarterly cash dividend of seventy-seven cents ($0.77) per share of common stock, payable February 20, 2016, to stockholders of record at the close of business on January 20, 2016.

Facebook Inc (NASDAQ:FB) shares moved up 0.31% in last trading session and ended the day at $95.26. FB Gross Margin is 83.10% and its has a return on assets of 6.50%. Facebook Inc (NASDAQ:FB) quarterly performance is -2.34%.

On 11 January, Facebook Inc (NASDAQ:FB) has become the only Internet firm to side with telecom operators over the issue of differential pricing of data services.

Alphabet Inc (NASDAQ:GOOG) caters to the Technology space. Its weekly performance is -1.99%. On the last day of trading company shares ended up at $701.79. Alphabet Inc (NASDAQ:GOOG) distance from 50-day simple moving average (SMA50) is -7.57%.

Alphabet Inc (NASDAQ:GOOG) said that, it is taking the necessary measures to counter Facebook’s push to VR advertising with both affordable VR gadgets and ambitious technology projects.

Symetra Financial Corporation (NYSE:SYA) shares increased 0.19% in last trading session and ended the day at $31.91. SYA has a return on assets of 0.50%. Symetra Financial Corporation (NYSE:SYA) quarterly performance is 0.89%.

Symetra Financial Corporation (NYSE:SYA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Analyst Ratings.Net reports.

BioLineRx, Ltd. (NASDAQ:BLRX) caters to the Healthcare space. Its weekly performance is -7.77%. On the last day of trading company shares ended up at $0.95. BioLineRx, Ltd. (NASDAQ:BLRX) distance from 50-day simple moving average (SMA50) is -7.95%.

On 12 January, BioLineRx, Ltd. (NASDAQ:BLRX) announced a collaboration with MSD, known as Merck in the US and Canada, to support a Phase 2 study investigating BioLineRx’s BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The study is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of this combination in patients with metastatic pancreatic adenocarcinoma.